Synergism between resveratrol and other phytochemicals: Implications for obesity and osteoporosis

Molecular Nutrition and Food Research

Volumn 55, Issue 8, 2011, Pages 1177-1185

  Rayalam, Srujana ^a   Della Fera, Mary Anne ^a   Baile, Clifton A ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Adipocyte life cycle; Multifocal signal modulation therapy; Osteogenesis; Synergistic activity

Indexed keywords

RESVERATROL; STILBENE DERIVATIVE;

ADIPOCYTE; ANIMAL; CALORIC RESTRICTION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; LIPOLYSIS; OBESITY; OSTEOBLAST; OSTEOPOROSIS; PHYSIOLOGY; REVIEW;

ADIPOCYTES; ANIMALS; CALORIC RESTRICTION; DRUG SYNERGISM; HUMANS; LIPOLYSIS; OBESITY; OSTEOBLASTS; OSTEOPOROSIS; STILBENES;

MURINAE; RATTUS;

EID: 79960110969     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201000616     Document Type: Review

References (76)

1. Masoro, E. J., Caloric restriction and aging: an update. Exp. Gerontol. 2000, 35, 299-305.
2. Finkel, T., Ageing: a toast to long life. Nature 2003, 425, 132-133.
3. Kaeberlein, M., McVey, M., Guarente, L., The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999, 13, 2570-2580.
4. Tissenbaum, H. A., Guarente, L., Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410, 227-230.
5. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W. et al., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
6. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A. et al., Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337-342.
7. U.S. Department of Health and Human Services, Washington, DC 2004.
8. Flegal, K. M., Carroll, M. D., Ogden, C. L., Curtin, L. R., Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303, 235-241.
9. Wang, Y., Beydoun, M. A., Liang, L., Caballero, B., Kumanyika, S. K., Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity 2008, 16, 2323-2330.
10. Smith, J., Al-Amri, M., Dorairaj, P., Sniderman, A., The adipocyte life cycle hypothesis. Clin. Sci. 2006, 110, 1-9.
11. Jezierska-Wozniak, K., Nosarzewska, D., Tutas, A., Mikolajczyk, A. et al., Use of adipose tissue as a source of mesenchymal stem cells. Postepy Hig. Med. Dosw. 2010, 64, 326-332.
12. Lendeckel, S., Jodicke, A., Christophis, P., Heidinger, K. et al., Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. J. Craniomaxillofac. Surg. 2004, 32, 370-373.
13. Gregoire, F. M., Smas, C. M., Sul, H. S., Understanding adipocyte differentiation. Physiol. Rev. 1998, 78, 783-809.
14. Rayalam, S., Della-Fera, M. A., Baile, C. A., Phytochemicals and regulation of the adipocyte life cycle. J. Nutr. Biochem. 2008, 19, 717-726.
15. Rayalam, S., Yang, J. Y., Della-Fera, M. A., Park, H. J. et al., Anti-obesity effects of xanthohumol plus guggulsterone in 3T3-L1 adipocytes. J. Med. Food 2009, 12, 846-853.
16. Rayalam, S., Della-Fera, M. A., Yang, J. Y., Park, H. J. et al., Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J. Nutr. 2007, 137, 2668-2673.
17. Pei, L., Tontonoz, P., Fat's loss is bone's gain. J. Clin. Invest. 2004, 113, 805-806.
18. Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M. et al., PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 2004, 113, 846-855.
19. Goldring, S. R., Goldring, M. B., Eating bone or adding it: the Wnt pathway decides. Nat. Med. 2007, 13, 133-134.
20. Backesjo, C. M., Li, Y., Lindgren, U., Haldosen, L. A., Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs 2009, 189, 93-97.
21. Backesjo, C. M., Li, Y., Lindgren, U., Haldosen, L. A., Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner. Res. 2006, 21, 993-1002.
22. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A. et al., Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429, 771-776.
23. Pang, W. J., Sun, S. D., Bai, L., Yang, Y. J., Yang, G. S., Effects of resveratrol on pig primary preadipocytes proliferation, differentiation and transcription expression of Sirt1 gene. Sheng Wu Gong Cheng Xue Bao 2006, 22, 850-855.
24. Rayalam, S., Yang, J. Y., Ambati, S., Della-Fera, M. A., Baile, C. A., Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother. Res. 2008, 22, 1367-1371.
25. Ferry-Dumazet, H., Garnier, O., Mamani-Matsuda, M., Vercauteren, J. et al., Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis 2002, 23, 1327-1333.
26. Liang, Y. C., Tsai, S. H., Chen, L., Lin-Shiau, S. Y., Lin, J. K., Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem. Pharmacol. 2003, 65, 1053-1060.
27. Fischer-Posovszky, P., Kukulus, V., Tews, D., Unterkircher, T. et al., Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am. J. Clin. Nutr. 2010, 92, 5-15.
28. Mader, I., Wabitsch, M., Debatin, K. M., Fischer-Posovszky, P., Fulda, S., Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J. 2010, 24, 1997-2009.
29. Hsu, C. L., Yen, G. C., Induction of cell apoptosis in 3T3-L1 pre-adipocytes by flavonoids is associated with their antioxidant activity. Mol. Nutr. Food Res. 2006, 50, 1072-1079.
30. Londos, C., Brasaemle, D. L., Schultz, C. J., Adler-Wailes, D. C. et al., On the control of lipolysis in adipocytes. Ann. N Y Acad. Sci. 1999, 892, 155-168.
31. Szkudelska, K., Nogowski, L., Szkudelski, T., Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J. Steroid Biochem. Mol. Biol. 2009, 113, 17-24.
32. Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P. et al., Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434, 113-118.
33. Lin, J., Wu, H., Tarr, P. T., Zhang, C. Y. et al., Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418, 797-801.
34. Gerhart-Hines, Z., Rodgers, J. T., Bare, O., Lerin, C. et al., Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO. J. 2007, 26, 1913-1923.
35. Szkudelska, K., Nogowski, L., Szkudelski, T., Resveratrol and genistein as adenosine triphosphate-depleting agents in fat cells. Metabolism 2010. inpress, Doi: 10.1016/metabol:2010.07.006.
36. Subbaramaiah, K., Dannenberg, A. J., Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 2003, 24, 96-102.
37. Elmali, N., Baysal, O., Harma, A., Esenkaya, I., Mizrak, B., Effects of resveratrol in inflammatory arthritis. Inflammation 2007, 30, 1-6.
38. Ma, Z. H., Ma, Q. Y., Wang, L. C., Sha, H. C. et al., Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. Inflamm. Res. 2005, 54, 522-527.
39. Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., Sethi, G., Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 2006, 72, 1605-1621.
40. Fain, J. N., Madan, A. K., Hiler, M. L., Cheema, P., Bahouth, S. W., Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145, 2273-2282.
41. Gonzales, A. M., Orlando, R. A., Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr. Metab. 2008, 5, 17.
42. Ahn, J., Lee, H., Kim, S., Ha, T., Resveratrol inhibits TNF-alpha-induced changes of adipokines in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2007, 364, 972-977.
43. Kundu, J. K., Surh, Y. J., Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat. Res. 2004, 555, 65-80.
44. Leonard, S. S., Xia, C., Jiang, B. H., Stinefelt, B. et al., Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 2003, 309, 1017-1026.
45. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H. et al., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127, 1109-1122.
46. Um, J. H., Park, S. J., Kang, H., Yang, S. et al., AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59, 554-563.
47. Canto, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M. et al., AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009, 458, 1056-1060.
48. Canto, C., Auwerx, J., PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20, 98-105.
49. Barger, J. L., Kayo, T., Vann, J. M., Arias, E. B. et al., A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 3, e2264.
50. Ponugoti, B., Kim, D. H., Xiao, Z., Smith, Z. et al., SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 2010, 285, 33959-33970.
51. Ramadori, G., Gautron, L., Fujikawa, T., Vianna, C. R. et al., Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009, 150, 5326-5333.
52. Borriello, A., Cucciolla, V., Della Ragione, F., Galletti, P., Dietary polyphenols: focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutr. Metab. Cardiovasc. Dis. 2010, 20, 618-625.
53. Boissy, P., Andersen, T. L., Abdallah, B. M., Kassem, M. et al., Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 2005, 65, 9943-9952.
54. Lee, Y. S., Kim, Y. S., Lee, S. Y., Kim, G. H. et al., AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 47, 926-937.
55. Dai, Z., Li, Y., Quarles, L. D., Song, T. et al., Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 2007, 14, 806-814.
56. Zhou, H., Shang, L., Li, X., Zhang, X. et al., Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells. Exp. Cell Res. 2009, 315, 2953-2962.
57. Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C., Klinge, C. M., Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141, 3657-3667.
58. Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L. et al., Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8, 157-168.
59. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., Walle, U. K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
60. De Santi, C., Pietrabissa, A., Mosca, F., Pacifici, G. M., Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 2000, 30, 1047-1054.
61. De Santi, C., Pietrabissa, A., Spisni, R., Mosca, F., Pacifici, G. M., Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 2000, 30, 609-617.
62. De Santi, C., Pietrabissa, A., Spisni, R., Mosca, F., Pacifici, G. M., Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 2000, 30, 857-866.
63. Park, H. J., Della-Fera, M. A., Hausman, D. B., Rayalam, S. et al., Genistein inhibits differentiation of primary human adipocytes. J. Nutr. Biochem. 2009, 20, 140-148.
64. Kim, H. K., Nelson-Dooley, C., Della-Fera, M. A., Yang, J. Y. et al., Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J. Nutr. 2006, 136, 409-414.
65. Yang, J. Y., Della-Fera, M. A., Rayalam, S., Ambati, S. et al., Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci. 2008, 82, 1032-1039.
66. Kuppusamy, U. R., Das, N. P., Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilization in rat adipocytes. Biochem. Pharmacol. 1992, 44, 1307-1315.
67. Park, H. J., Yang, J. Y., Ambati, S., Della-Fera, M. A. et al., Combined effects of genistein, quercetin and resveratrol in human and 3T3-L1 adipocytes. J. Med. Food 2008, 11, 773-783.
68. Lai, C. Y., Yang, J. Y., Rayalam, S., Della-Fera, M. A. et al., Preventing bone loss and weight gain with combinations of vitamin D and phytochemicals. J. Med. Food 2010, in press, DOI:10.1089/gmf.2010.0232.
69. Sakaguchi, K., Morita, I., Murota, S., Relationship between the ability to support differentiation of osteoclast-like cells and adipogenesis in murine stromal cells derived from bone marrow. Prostaglandins Leukot. Essent. Fatty Acids 2000, 62, 319-327.
70. Rosen, C. J., Bouxsein, M. L., Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol. 2006, 2, 35-43.
71. Mukherjee, S., Dudley, J. I., Das, D. K., Dose-dependency of resveratrol in providing health benefits. Dose Response 2010, 8, 478-500.
72. Wilson, T., Knight, T. J., Beitz, D. C., Lewis, D. S., Engen, R. L., Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci. 1996, 59, PL15-PL21.
73. Crowell, J. A., Korytko, P. J., Morrissey, R. L., Booth, T. D., Levine, B. S., Resveratrol-associated renal toxicity. Toxicol. Sci. 2004, 82, 614-619.
74. Kapetanovic, I. M., Muzzio, M., Huang, Z., Thompson, T. N., McCormick, D. L., Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 2010, inpress, DOI:10.1007/s00280010-1525-4.
75. Wenzel, E., Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005, 49, 472-481.
76. Baile, C. A., Yang, J. Y., Rayalam, S., Hartzell, D. L. et al., Effect of resveratrol on fat mobilization. Ann. N Y Acad. Sci. 2011, 1215, 40-47.